Editor Profile

Carlos del Rio, MD

Chief Editor, HIV/AIDS

About the NEJM Journal Watch Infectious Diseases Board

Carlos del Rio, MD, is Hubert Professor and Chair of the Hubert Department of Global Health, Rollins School of Public Health at Emory University, and Co-Director of the Emory Center of AIDS Research. He is also the Program Director and Principal Investigator of the Emory AIDS International Training and Research Program. His research interests include the epidemiology of opportunistic infections in HIV, the epidemiology and transmission dynamics of HIV and other sexually transmitted diseases, early diagnosis of HIV, linkage to and retention in HIV care, and prevention of HIV infection. In addition, Dr. del Rio's interests include the optimization of HIV management in resource-constrained countries. He was a member of the NEJM Journal Watch AIDS Clinical Care Editorial Board since 1998 and Editor-in-Chief since 2014. Dr. del Rio has been a member of the NEJM Journal Watch Infectious Diseases Editorial Board since May 2014.


Consultant / Advisory board


Grant / Research support

National Institutes of Health (NIH); NIH/National Institute of Allergy and Infectious Diseases; Centers for Disease Control and Prevention; NIH/National Institute on Drug Abuse; Addis Ababa University

Editorial boards

AIDS Research and Human Retroviruses; Journal of AIDS

Leadership positions in professional societies

HIV Medicine Association (Board of Directors); International Antiviral Society–USA (Board of Directors)

Summaries by Carlos del Rio

  • October 6, 2015

    Cancer Among HIV-Infected People in North AmericaFree

    1. Carlos del Rio, MD

    Cumulative incidence remains highest for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer, but rates of anal, colorectal, and liver cancers are increasing.

  • October 5, 2015

    HIV Prevalence in the U.S., 2007–2012

    1. Carlos del Rio, MD and
    2. Eli Rosenberg, PhD

    Based on the CDC's National Health and Nutrition Examination Survey, 0.39% of adults aged 18 to 59 were living with HIV infection.

  • September 22, 2015

    Intimate Partner Violence and Care Engagement in HIV-Infected Women

    1. Carlos del Rio, MD and
    2. Ameeta Kalokhe, MD, MSc

    A meta-analysis suggests that IPV is associated with decreased likelihood of antiretroviral therapy use, regimen adherence, and virologic suppression.

  • September 15, 2015

    Time to Be PROUD of the Effectiveness of PrEP

    1. Carlos del Rio, MD

    The effectiveness of PrEP using tenofovir/FTC was higher in this “real-world” study than in randomized, controlled trials.

  • September 11, 2015

    PrEP Works in Clinical PracticeFree

    1. Carlos del Rio, MD and
    2. Colleen F. Kelley, MD, MPH

    Kaiser Permanente members who initiated PrEP had no new HIV infections during 388 person-years of follow-up, despite high rates of other sexually transmitted diseases.

  • September 9, 2015

    Nanoformulations of Antiretrovirals Might Improve PrEP Effectiveness

    1. Carlos del Rio, MD

    A nanoparticle formulation of rilpivirine, topically applied in a thermosensitive gel, coated the reproductive tract of humanized mice and protected them from HIV infection after vaginal challenge.